secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001104659-23-124293
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA Q4 revenue down 78% to $780K; net loss widens to $3.6M
------------------------------------------------------------------

- Total revenues $780K vs $3.6M YoY; COVID testing contract with CUNY canceled in June 2023.
- Gross profit $79K (10% margin) vs $417K (12%) YoY.
- Operating loss $4.2M improved slightly from $4.3M; net loss $3.6M vs $665K YoY.
- Cash and equivalents $7.2M at Sep 30, 2023, down from $10.8M at Jun 30, 2023.
- CEO cites biotherapeutic pivot momentum; GMP capacity expected online H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465923124293/0001104659-23-124293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465923124293/tm2332417d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-124293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer